Dr. Radvanyi will be chairing the session, "Immunomodulatory Therapeutic Antibodies for Cancer: Discovery and Development of the Next Wave of Checkpoint Inhibitors" on
To manufacture TIL therapy, Lion's lead product candidate for the treatment of metastatic melanoma, TILs extracted from the patient's tumor must be expanded by thousands in a laboratory before being injected back into the patient. Dr. Radvanyi's research has shown that manipulating specific costimulatory pathways during TIL expansion can greatly enhance the function and survival capacity of these cells for therapeutic purposes.
In addition, Dr. Radvanyi's group has identified a number of novel biomarkers that distinguish patients who respond to TIL therapy, as well as markers that can be targeted in patients who fail to respond. These will form the basis of novel TIL combination therapies that Lion intends to develop in collaboration with academic collaborators.
One of the world's foremost experts on TILs, Dr. Radvanyi joined Lion as CSO in
ImVacS brings together a global audience of vaccine researchers and developers of cancer immunotherapies for five focused meetings that explore the frontiers of immunology as the basis for patient treatment. Top researchers from around the world gather to discuss new data, new approaches and novel science from industry, academia, regulatory, and research institutes. For the conference program and more information, please visit www.imvacs.com.
Forward Looking Statements
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that manipulating specific costimulatory pathways during TIL expansion can be effective for therapeutic purposes, or that effective biomarkers that distinguish patients who respond to TIL therapy can be successfully developed, and, in particular, that the Company's TILs technologies can be further successfully developed or commercialized. Additional risks and uncertainties are described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Investor Relations
The Trout Group Gitanjali Jain Ogawa646-378-2949 email@example.com